Boiron (FRA:BON) ROE % Adjusted to Book Value : 4.93% (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Boiron ROE % Adjusted to Book Value?

Boiron's ROE % for the quarter that ended in Dec. 2023 was 8.62%. Boiron's PB Ratio for the quarter that ended in Dec. 2023 was 1.75. Boiron's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was 4.93%.

Boiron ROE % Adjusted to Book Value Historical Data

The historical data trend for Boiron's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boiron ROE % Adjusted to Book Value Chart

Boiron Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

6.51

3.77

4.77

5.43

4.30

Boiron Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															12.97	3.57	7.81	4.61	4.93

Competitive Comparison of Boiron's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Boiron's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Boiron's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Boiron's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Boiron's ROE % Adjusted to Book Value falls into.

Boiron ROE % Adjusted to Book Value Calculation

Boiron's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	7.53%	/	1.75
	=	4.30%

Boiron's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	8.62%	/	1.75
	=	4.93%

Boiron ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Boiron's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Boiron (FRA:BON) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Boiron SA (FRA:BON) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

BOIRF:USA BOI:France BON:Germany

Address

2, Avenue de l’Ouest Lyonnais No. 039, Messimy, FRA, 69510

Website

http://www.boiron.com

Boiron is a drug manufacturer that focuses on homeopathic products. The company's revenue is roughly split between its nonproprietary homeopathic medicines and products in its over-the-counter specialties category. Boiron's nonproprietary medicines are generic products that do not refer to any therapeutic indication, while the specialties category includes first-resort products provided in tablet form, are bottled to use as drops, syrups, or ointments. Geographical segments are France, Europe, North America, and other countries. It generates a majority of revenue from France. The company's products include Oscillococcinum, Stodal and Stodaline, Arnigel, Camilia, Sedatif PC, Coryzalia, Homeoptic, and Homeovox.